SEC 13F Intelligence

Altium Capital Management LLC / CN2

Altium Capital Management LLC’s Catalyst Pharmaceuticals Inc Position

Does Altium Capital Management LLC own Catalyst Pharmaceuticals Inc (CN2)? Not currently — the last reported position was 255.0K shares worth $5M in Q4 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$5M
Q4 2024
Shares
255.0K
% of Portfolio
+1.51%
Quarters Held
5
position exited

Position History CN2

Reported value by quarter
Q4 ’23: $6MQ4 ’23Q1 ’24: $8MQ1 ’24Q2 ’24: $8MQ2 ’24Q3 ’24: $8MQ3 ’24Q4 ’24: $5MQ4 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q4 2024255.0K$5M+1.51%
Q3 2024385.0K$8M+2.25%
Q2 2024500.0K$8M+3.16%
Q1 2024500.0K$8M+3.15%
Q4 2023385.0K$6M+4.39%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Altium Capital Management LLC’s full portfolio or all institutional holders of CN2.